A Proposal to End the COVID-19 Pandemic /

Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existi...

Descrición completa

Detalles Bibliográficos
Autor Principal: Agarwal, Ruchir
Outros autores: Gopinath, Gita
Formato: Revista
Idioma:English
Publicado: Washington, D.C. : International Monetary Fund, 2021.
Acceso en liña:Full text available on IMF
LEADER 02571cas a2200217 a 4500
001 AALejournalIMF021882
008 230101c9999 xx r poo 0 0eng d
020 |z 9781513593678 
040 |a BD-DhAAL  |c BD-DhAAL 
100 1 |a Agarwal, Ruchir. 
240 1 0 |a A Proposal to End the COVID-19 Pandemic.  |l Italian 
245 1 2 |a A Proposal to End the COVID-19 Pandemic /  |c Ruchir Agarwal, Gita Gopinath. 
264 1 |a Washington, D.C. :  |b International Monetary Fund,  |c 2021. 
300 |a 1 online resource (53 pages) 
500 |a <strong>Off-Campus Access:</strong> No User ID or Password Required 
500 |a <strong>On-Campus Access:</strong> No User ID or Password Required 
506 |a Electronic access restricted to authorized BRAC University faculty, staff and students 
520 3 |a Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on existing initiatives, this paper proposes pragmatic actions at the national and multilateral level to expeditiously defeat the pandemic. The proposal targets: (1) vaccinating at least 40 percent of the population in all countries by the end of 2021 and at least 60 percent by the first half of 2022, (2) tracking and insuring against downside risks, and (3) ensuring widespread testing and tracing, maintaining adequate stocks of therapeutics, and enforcing public health measures in places where vaccine coverage is low. The benefits of such measures at about USD 9 trillion far outweigh the costs which are estimated to be around USD 50 billion-of which USD 35 billion should be paid by grants from donors and the residual by national governments potentially with the support of concessional financing from bilateral and multilateral agencies. The grant funding gap identified by the Access to COVID-19 Tools (ACT) Accelerator amounts to about USD 22 billion, which the G20 recognizes as important to address. This leaves an estimated USD 13 billion in additional grant contributions needed to finance our proposal. Importantly, the strategy requires global cooperation to secure upfront financing, upfront vaccine donations, and at-risk investment to insure against downside risks for the world. 
538 |a Mode of access: Internet 
700 1 |a Gopinath, Gita. 
856 4 0 |z Full text available on IMF  |u http://elibrary.imf.org/view/journals/006/2021/004/006.2021.issue-004-it.xml  |z IMF e-Library